Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion by Toussaint, L Gerard et al.
UC San Francisco
UC San Francisco Previously Published Works
Title
Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma 
cell invasion
Permalink
https://escholarship.org/uc/item/9zt4z1zb
Journal
Molecular Cancer, 11(1)
ISSN
1476-4598
Authors
Toussaint, L
Nilson, Allan E
Goble, Jennie M
et al.
Publication Date
2012-05-14
DOI
http://dx.doi.org/10.1186/1476-4598-11-32
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Toussaint et al. Molecular Cancer 2012, 11:32
http://www.molecular-cancer.com/content/11/1/32RESEARCH Open AccessGalectin-1, a gene preferentially expressed at the
tumor margin, promotes glioblastoma cell
invasion
L Gerard Toussaint III1,2*, Allan E Nilson3, Jennie M Goble3, Karla V Ballman4, C David James5, Florence Lefranc6,7,
Robert Kiss7 and Joon H Uhm3Abstract
Background: High-grade gliomas, including glioblastomas (GBMs), are recalcitrant to local therapy in part because
of their ability to invade the normal brain parenchyma surrounding these tumors. Animal models capable of
recapitulating glioblastoma invasion may help identify mediators of this aggressive phenotype.
Methods: Patient-derived glioblastoma lines have been propagated in our laboratories and orthotopically
xenografted into the brains of immunocompromized mice. Invasive cells at the tumor periphery were isolated using
laser capture microdissection. The mRNA expression profile of these cells was compared to expression at the tumor
core, using normal mouse brain to control for host contamination. Galectin-1, a target identified by screening the
resulting data, was stably over-expressed in the U87MG cell line. Sub-clones were assayed for attachment,
proliferation, migration, invasion, and in vivo tumor phenotype.
Results: Expression microarray data identified galectin-1 as the most potent marker (p-value 4.0 x 10-8) to identify
GBM cells between tumor-brain interface as compared to the tumor core. Over-expression of galectin-1 enhanced
migration and invasion in vitro. In vivo, tumors expressing high galectin-1 levels showed enhanced invasion and
decreased host survival.
Conclusions: In conclusion, cells at the margin of glioblastoma, in comparison to tumor core cells, have enhanced
expression of mediators of invasion. Galectin-1 is likely one such mediator. Previous studies, along with the current
one, have proven galectin-1 to be important in the migration and invasion of glioblastoma cells, in GBM
neoangiogenesis, and also, potentially, in GBM immune privilege. Targeting this molecule may offer clinical
improvement to the current standard of glioblastoma therapy, i.e. radiation, temozolomide, anti-angiogenic therapy,
and vaccinotherapy.
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In spite of recent advances in the treatment of patients
with glioblastoma, the prognosis for those afflicted
remains poor. Even when these tumors harbor a favor-
able gene methylation profile, the newest standard of
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distribution, and reproduction in any mediumoffers a median survival of less than two years [2]. Al-
though extent of surgical resection is an important pre-
dictor of patient survival [3,4], local therapy for
glioblastoma fails because microscopically invasive cells
evade resection and eventually proliferate in spite of ad-
juvant chemoradiotherapy [5,6]. Controlling the invasive
nature of this tumor may offer hope for more efficacious
local therapy, improved quality of life, and perhaps better
response to adjuvant therapies [5,6].
Numerous mediators of glioma cell migration and in-
vasion have been identified, ranging from integrins [7,8]
to focal adhesion proteins [9,10] and from upstreamntral Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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and serine- [14] proteases. Galectin-1 has also been iden-
tified as a key player in GBM cell migration [15]. The
majority of these mediators were investigated in glioma
because of their role in promoting cell migration in other
cancers. Other mediators of GBM cell migration
have been identified when investigators isolated invasive
cells at the edge of glioblastomas and compared their
gene expression to the cells collected from the tumor
core [16-19]. In parallel, galectin-1 has been demon-
strated to be more expressed in the invasive part
of GBMs when compared to GBM core [20,21], while
providing chemoresistance [22] and pro-angiogenic singals
[23,24] to glioblastomas.
In this study, we investigated whether our patient-
derived glioblastoma xenograft panel could reproduce
the molecular signature of invasion seen in the human
disease. Further, we hypothesized that expression of inva-
sion mediators, and Galectin-1 specifically, would be ele-
vated at the tumor-brain interface. By comparing
microarray expression data from GBM cells at the tumor
core to data from cells at the invasive edge, a list of the
top 200 differentially expressed genes (by p-value) was
subjected to a filtering algorithm. Galectin-1 was ranked
at the top of this list. We thus took advantage of our
own patient-derived glioblastoma xenograft model [25]
in order to further decipher the roles of galectin-1 on
GBM cell migration features. The system we have devel-
oped mitigates the effect of three important confounders
from human samples. First, tissue is frozen within one
minute of removal, ensuring high quality RNA. Second,
the tumors grown typically do not reach sizes large
enough to undergo necrosis at the tumor core, further
assuring quality RNA from the tumor core and making
the comparison of core to invasive edge more strictly re-
flective of the presence or absence of invasion (rather
than hypoxia/necrosis versus invasion). Finally, the xeno-
graft setting allows for harvesting of normal host brain
from regions remote from the tumor, which serve as a
control for possible contamination of samples microdis-
sected at the tumor-brain interface. Galectin-1 was thus
identified in this unsupervised method of analysis as a
key marker of glioma invasion, while validating the
novel filtering method (used to control for sample con-
tamination) presented in this study.
Materials and methods
Human tumor line propagation
Patient-derived glioblastoma lines have been propagated
in our laboratories as described previously [25,26].
Twenty-two separate human xenograft lines have been
created and propagated. Of those, six were chosen for
this study, representing varying known genetic altera-
tions present in glioblastoma (e.g. EGFR amplification ormutation, PTEN deletion, p53 mutation, etc.). The use of
human tissue to create these xenograft lines was per-
formed in accordance with NIH guidelines and under
approval of the Mayo Clinic Institutional Review Board
(IRB protocol #802-04).Mouse orthopic xenografts
All nude mice (Hsd:Athymic Nude-Foxn1nu- Harlan
Laboratories, Indianapolis, IN) used in this project were
treated in compliance with NIH and institutional guide-
lines. These protocols were reviewed and approved by
the Mayo Clinic Institutional Animal Care and Use
Committee (IACUC protocols #84-05, #A279-09,
#A688-11). Glioblastoma cells were injected intracrani-
ally into anesthetized mice following our laboratory
protocol [25].
The U87MG (human glioblastoma cell line, ATCC
Number: HTB-14™, ATCC, Manassas, VA) xenograft
experiments were powered to have an 80% chance of
detecting a change in xenograft survival of 10 days with
a p-value of 0.05. Ten animals were needed per compari-
son group. Following injection, the mice were observed
at least once daily until onset of neurological symptoms.
At that time, animals were euthanized and their brains
removed and either frozen using Optimal Cutting
Temperature (OCT) compound (Electron Microscopy
Sciences, Fort Washington, PA) in cryomolds placed
atop dry ice, or fixed in 10% buffered formalin and paraf-
fin embedded for histopathological analysis.
The symptom-free survival of nude mice harboring
U87MG parental versus transfected xenografts was com-
pared. Kaplan-Meyer survival curves were generated and
comparisons made by Log-Rank testing.Laser capture microdissection
Laser capture microdissection was used to collect sam-
ples from frozen, stained (HistoGene, Arcturus, Moun-
tain View, CA), and dehydrated slides using previously
published methods [27] on a PixCell IIe Laser Capture
Microscope (Arcturus, Mountain View, CA). From the
tumor cores, 3000 to 5500 cells per slide were collected,
while the tumor edge allowed for collection of 300–900
cells per slide. Approximately 1000 to 2000 cells were
collected from each sample of normal mouse brain
(Figure 1).RNA isolation, quantitation, and quality control
The CapSure HS (Arcturus, Mountain View, CA) caps
holding microdissected cells were coupled to their corre-
sponding extraction buffer reservoirs. The column-based
PicoPure RNA isolation kit (Arcturus, Mountain View,
CA) was used to extract RNA from collected cells per
manufacturer instructions.
Figure 1 Three geographic tumor regions targeted for RNA isolation. Using laser-capture microdissection, tumor cells were isolated from the
cell-dense tumor core and the tumor-brain interface. For comparison, cells were also collected from unaffected areas of the normal mouse brain.
Modified with author permission [25].
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pooled onto three separate columns (tumor core, tumor
periphery, and normal brain) and totalRNA was eluted at
the final step into a final volume of 11 microliters. One
microliter of each eluted RNA sample was used for
quantitation with the RiboGreen (Molecular Probes, Eu-
gene, OR) assay kit. These total RNA samples were ana-
lyzed for integrity by obtaining electropherograms on an
Agilent 2100 Bioanalyzer chip. Samples of acceptable
quality based on RNA integrity number (2100 Expert
software, Agilent Technologies, Inc. Palo Alto, CA) and
plot profile (18 S and 28 S peaks with no degradation
peaks) were processed for eventual chip hybridization as
follows.
RNA amplification and chip hybridization
Each sample was processed at the Mayo Clinic Genomic
Center Microarray Shared Resource strictly according to
Affymetrix small-sample protocol recommendations, and
GeneChip hybridization followed our standard protocol
[28]. After washes, arrays were scanned using the Gene-
Chip Scanner 3000 (Affymetrix, Santa Clara, CA). Light
intensity data from all spots on each chip were recorded
as .cel files, stored on an internal server, and written to a
digital variable disc (DVD).
Data normalization and filtering
Raw data from chip hybridization experiments were nor-
malized across chips and across probesets using a fast
linear Loess routine [29], known as Fastlo. This
normalization routine, in some respects similar to GC-
RMA, does not subtract mismatch probe hybridization
intensity from perfect match data. As a result, thereproducibility of the data is more robust (i.e., smaller p-
values), while the fold-change ratios are not as extreme
as with routines that use mismatch probe data in
normalization.
By comparing expression data from cells at the tumor
core to data from cells at the invasive edge, a list of the
top 200 differentially expressed genes (by p-value) was
subjected to a filtering algorithm. This algorithm was
designed to minimize the effect of potential contamin-
ation of the edge samples with normal mouse brain cells.
Relative expression values for each gene from tumor
core, tumor edge, and normal mouse brain samples were
compared. Genes of interest were identified that met
three criteria: a) low expression at tumor core; b) rela-
tively increased expression at tumor periphery; and c)
lower signal (relative to tumor periphery) generated from
surrounding rodent brain parenchyma. This profile obvi-
ates the concern that genes upregulated at the tumor
edge might be identified because of cross-hybridization
from mouse cells contaminating these edge samples.
Conversely, genes were considered of interest if the op-
posite were true: lowest relative expression value at the
tumor edge compared to tumor core and normal brain.
The genes meeting this ideal profile were ranked by p-
value (between core and edge).Immunohistochemistry
Formalin-fixed paraffin-embedded sections were stained
using an ABC kit (Vector Laboratories, Burlingame, CA)
after steam antigen retrieval. Primary antibodies included a
mouse monoclonal anti-galectin-1 antibody (Research
Diagnostics, INC, New Jersey) along with a human-specific
mouse monoclonal anti-vimentin antibody (Dakocytomation,
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anti-mouse secondary antibody, staining developed with
NovaRed Developing Reagent (Vector Laboratories, Burlin-
game, CA). Sections were permanently mounted with Vecta-
mount (Vector Laboratories, Burlingame, CA). Images were
captured electronically.
Vector creation
A cDNA clone of human galectin-1 was obtained from
ATCC in the pOTB7 vector (ATCC #MGC-1818) and
amplified using primers harboring BglII (forward) and
SalI (reverse) sites:
 forward - CGGATCAGATCTTGTAAAACGACGG
CCAGTAAC,
 reverse - CATCGTTGTCGACATGGGCTGGCTG
ATTTCAGTC),
Both this PCR product and the pIRES2-acGFP1 vector
(Clontech, Mountain View, CA) were cut, using these re-
striction sites, subsequently gel purified, and finally
ligated together (Roche Rapid Ligation Kit, Roche). The
resulting pIRES2-Gal1-acGFP1 vector was transformed
into Top10 cells (Invitrogen, Eugene, OR) for amplifica-
tion. In parallel, a PCR reaction with primers harboring
the same useful restriction sites (BglII forward and SalI
reverse) was used to duplicate the acGFP1 sequence:
 forward – CGGATCAGATCTATGGTGAGCAAGG
GCGCCGAG,
 reverse - CATCGTTGTCGACGCGGCCGCTCAC
TTGTAC.
This sequence was inserted into the multiple cloning
site of the same vector pIRES2-acGFP1 to create one
vector harboring two copies of acGFP. This circum-
vented a common problem with IRES vectors – inability
to transcribe the transcript following the IRES sequence
if the first MCS is empty. The new pIRES2-acGFP1-
acGFP1 vector was used as a control for the pIRES2-
Gal1-acGFP1 construct. Both vectors were sequenced
through their multiple cloning sites to ensure no PCR-
induced mutations were present.
Transfection and stable clone generation
The U87MG human glioma cell line was kept in tissue
culture in DMEM (Cellgro Mediatech, Inc.), with 10% fetal
bovine serum, and penicillin/streptomycin. For transfec-
tion, 2.5x106 cells were plated overnight on a 100 mm
round dish. Cells were transfected using 60μL of Superfect
reagent and 10μg of DNA in 10% fetal bovine serum
media. After incubation for 3 hours, the adhered cells were
washed four times with PBS and the media was
replaced with our standard incubation media. Geneticin(G418) selection began the day after transfection. When
enough GFP-expressing cells were identified, single cell
suspensions were sorted under sterile conditions using the
GFP filters (488/530 nm excitation/emission) on a FACS
Vantage Sorter (Beckton Dickinson Immunocytometry
Systems, San Jose, CA). Cells were collected in 96-well
plates at a setting of 2 cells / well, after attempts to collect
1 cell per well failed to produce any viable clones. The re-
mainder of the cells were collected and cultured under se-
lection as a mixed population of transfected cells. All
transfected cells were maintained in G418-containing
media during the entire experiment.
Western blotting
Lysates of cell pellets were made in 2X SDS sample buf-
fer (Invitrogen, Carlsbad, CA). Gels were run at 150
volts until adequate separation of the 35 kDa and 50 kDa
bands (60–90 minutes) of the Rainbow molecular
weight maker (Amersham, Piscataway, NJ). Proteins
were transferred to nitrocellulose and these membranes
were incubated with primary antibody for 60 minutes
(anti-Gal1 from Research Diagnostics, Flanders, New Jer-
sey, anti-beta actin from Sigma, St. Louis, Missouri).
After washing and incubation with secondary antibody
(Goat Anti-Mse IgG-HRP, Pierce, Rockford, IL), develop-
ing solution was added to the membrane (Supersignal
West Femto Substrate, Pierce, Rockford, IL). The time of
film exposure was adjusted for optimal signal to back-
ground ratio.
In vitro proliferation assays
Parental, control, and galectin-1 transfected U87MG
cells were plated at a density of 1000 cells/well, each in
eight wells of multiple 96-well plates. An MTS assay
(Promega, Madison, WI) was performed at six hours
after plating and daily thereafter until well overgrowth,
according to the manufacturer’s protocol. Eight wells
containing media alone were used to normalize the ab-
sorbance values of the other wells. Average corrected ab-
sorbance was compared between transfectant and
parental cells, using a t-test.
ECM attachment assays
Each well of a 96-well plate was incubated with 50μL of
a fibronectin (Invitrogen, Eugene, OR) solution at 5 ng/
μL. Once coated, parental, control, and galectin-1 trans-
fected U87MG cells were introduced at a density of
10,000cells/well with eight replicate wells per line. After
four hours, the media in half the wells was changed care-
fully – using a pipetteman rather than suction aspiration.
An MTT assay (Promega, Madison, WI) was
performed another four hours thereafter according to
manufacturer’s protocol. The plate was read the next
day, measuring absorbance at 570 nm and a reference
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data were normalized to the mean corrected absorbance
of the U87MG parental cells.
Radial migration assays
A two-dimensional radial migration assay was performed
as previously described [30,31]. In a blinded fashion,
various U87Gal-1 clones were analyzed and compared to
U87GFP controls and parental U87MG cells. Of each
clone, 2500 cells were allowed to sediment through a
cooled manifold onto laminin-coated cell culture wells
(Creative Scientific Methods, Inc., Phoenix, AZ). The
manifold and slide were incubated together overnight.
After removal of the manifold in the morning, an initial
photograph was made (t0) of the circular cell colony in
each well using an inverted microscope (Axiovert; Carl
Zeiss, Thornwood, NY). A follow-up photograph of each
cell colony was made at 24 hours. Using image analysis
software (Scion Image, Frederick, MD), the change in ra-
dius of each cell colony over 24 hours was calculated.
Data for each cell line was averaged over 10 wells and
compared between parental, control transfected, and
galectin-1 transfected cells. A t-test was applied to com-
pare means.
In vitro invasion assay
A modified Boyden chamber assay was performed using
known protocols [31]. One day after plating at uniform
density, 150,000 cells of each clone or line tested were
added to the top of rehydrated Matrigel Invasion Chambers
with 8micron pores (Becton Dickinson, Bedford, MA). We
used 10% fetal calf serum as the chemoattractant in the bot-
tom chamber. After 16 hours, the non-invading cells were
removed with cotton swabs. Those cells that had migrated
to the lower side of the membrane were fixed and stained
with hematoxylin. Stained membranes were removed from
the Boyden inserts, inverted, and permanently mounted on
glass slides using ProLong Anti-Fade (Invitrogen, Eugene,
OR). The invading cells on quadruplicate membranes were
quantitated by counting across a diameter of each mem-
brane under 40X microscopic magnification. Mean data
were normalized in each assay to the number of parental
cells invading the membranes; t-tests were used to deter-
mine statistical significance.
Results
Identification of galectin-1 as a potential mediator of
glioma invasion
The quantity of RNA obtained from various xenograft
tumors was highly variable. The average amount isolated
from cells at the tumor periphery was 56.7 ng (± 40.0 ng),
from the tumor core, 221 ng (± 109 ng), and from the nor-
mal mouse brain, 73.6 ng (± 38.2 ng). Across all three
regions, the average amount of RNA isolated per cell was6.8 pg +/− 4.2 pg. In spite of this variability, the quality of
the RNA was consistently high with a mean RNA integrity
number of 8.13± 0.74.
Expression microarray data suggested differential
hybridization of RNA isolated from the tumor core and
periphery for 12,796 separate probesets. The entire list of
over 54,000 probesets was filtered as described for candi-
date genes meeting our criteria for an ideal expression
profile. The resulting 8,969 probesets were ordered by p-
value. The probeset encoded 216405_at on the Affymetix
chip was at the top of this narrowed list, which hybri-
dized to mRNA encoding the galectin-1 protein (p-value
4.0 × 10-8). The fold change calculated using our
normalization routine was 2.04 in favor of the tumor-
brain interface as compared to the tumor core. This is in
comparison to a fold change of 4.31 when using Gene-
Spring, a commercially available program, with GC-
RMA normalization (Silicon Genetics division of Agilent
Technologies, Palo Alto, CA) (Figure 2).
Protein-level confirmation of microarray data
Paraffin sections of our patient-derived glioblastoma xeno-
grafts (15 of 22 lines) were stained for galectin-1 expres-
sion. Around half of the xenografts tested showed
preferential staining at the tumor-brain interface
(Figure 3). A few tumors stained in their entirety, and an-
other subset lacked significant staining. The 2 to 4 fold
change in galectin-1 mRNA expression at the tumor edge
compared to core may not have been sufficient to cause a
change in immunohistochemical staining. For those
tumors where there was staining of cells invading sur-
rounding host brain, we confirmed the human origin of
these remote cells with a human-specific antibody stain
(anti-vimentin). To control for the distinct isotypes of pri-
mary IgG, we stained parallel sections with a pooled IgG
control. This protein-level confirmation of our microarray
data gave us the impetus to pursue functional in vitro and
in vivo assays with galectin-1 over-expressing GBM cells.
Extracellular matrix attachment
The efficiency of attachment of U87MG cells to the
extracellular matrix (ECM) was compared to galectin-1
transfectants. A population of GFP-sorted cells (the
“Gal-1” bars in Figure 4A) was compared to its parental
counterpart. The number of metabolically-active cells
attached to fibronectin was no different between the two
lines at eight hours. Changing the media at four hours
reduced the number of cells left for labeling, but the ef-
fect was equal in both groups, suggesting a similar rate
of attachment for the two populations.
In vitro proliferation
Through cell sorting and selective clonal expansion,
clones of galectin-1 and acGFP-only transfectants were
Figure 2 The galectin-1 expression profile fits the criteria for a gene candidate that is relatively over-expressed at the tumor periphery.
These graphical representations of gene expression data compare the relative expression of galectin-1 from the core and edge of tumors to
pooled data from normal mouse brain samples. (Graphics from GeneSpringW).
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not enhance proliferation of the U87MG line (and hence
alter the interpretation of cell migration, cell invasion,
and host survival assays) we measured MTS incorpor-
ation over time. Indeed, galectin-1 clones grew at a rate
slightly, but not statistically significantly, lower than the
U87MG parental cell line and sorted GFP-only cells. The
growth rate of these cells rested between the rates of two
acGFP-only control clones (Figure 4B).
In vitro migration
The migratory rate of galectin-1 transfected cells was
compared to parental U87MG and acGFP-only controls.Cells over-expressing galectin-1 proved to have migra-
tory rates on laminin that were statistically significantly
faster than cells transfected with acGFP alone. The mi-
gratory rates of the U87 galectin-1 clones tested paral-
leled the trend in galectin-1 expression seen in western
blotting (Figure 4C).
In vitro invasion
A Boyden chamber transwell invasion assay was used to
assess the ability of various cell populations to invade
through a membrane coated with MatrigelW and posses-
sing 8μm pores. Overall, galectin-1 clones proved more
efficient in invasion than their acGFP-only counterparts
Figure 3 Galectin-1 immunohistochemistry confirms
preferential expression at the invasive edge of the
glioblastoma xenograft. (A) IgG control antibody (B) Galectin-1
staining (C) A human-specific vimentin antibody identifies all human
cells in the field.
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paralleled the level of galectin-1 expression (western
blotting) for each clone tested (Figure 4D).U87MG GBM xenograft-bearing mice survival
We assessed the survival of nude mice harboring xeno-
graft brain tumors induced by a few of our U87 galectin-
1 clones. Parental U87MG cells, along with galectin-1
and acGFP-only clones were injected into the right caud-
ate/putamen complex of nude mice. Tumors over-
expressing galectin-1 shortened survival of their hosts
compared to their parental counterparts (Figure 5). A
few animals (7/20) bearing tumors expressing acGFP
alone eventually exhibited neurological symptoms. The
examination of their brains suggested very little tumor
burden, and significant hydrocephalus was seen in a few(3/7). The remainder of these did not suffer neurological
decline, and the median survival was never reached.
Xenograft tumor morphology
All of our galectin-1 transfected clones generated tumors
in nude mice. The pattern of growth was compared at
the microscopic level to parental cells and those few
tumors generated from acGFP-only clones. Paraffin sec-
tions were stained with human-specific anti-vimentin
antibody to enhance the contrast between tumor cells
(brown) and host brain (blue counterstain, Figure 6).
The microscopic invasion shown for the galectin-1 trans-
fectants was seen frequently, albeit limited to the local
surrounding brain because U87MG tumors typically (see
the Discussion) show little invasion. Galectin-1 immuno-
histochemical staining of the U87 galectin-1 clone xeno-
grafts were ubiquitously positive, without discernable
overexpression at the tumor-brain interface.
Discussion
This study illustrates a novel microarray data filtering al-
gorithm that identified galectin-1 as a gene preferentially
expressed at the glioblastoma-brain interface. The
unique filtering of expression microarray data was made
possible by the ample amount of normal mouse brain
tissue available for dissection. In spite of species differ-
ences, cross-hybridization of mouse genetic material to
human probes did prove to be a common occurrence.
These data made it possible to control, rather stringently,
for the potential contamination of tumor edge samples
with mouse brain. Of course, there could still be possible
contamination – reactive mouse astrocytes expressing
unique genes that happen to cross-hybridize to the
human chip could have altered the expression profile at
the tumor-brain interface. Yet, this set of genes (those
uniquely up- or down-regulated in the host’s reactive
astrocytes around the xenograft tumor) must be orders
of magnitude smaller that the set of all possible cross-hy-
bridizing host genes.
The use of our animal model to identify mediators of
glioma invasion has the potential pitfall of identifying
artifacts of xenografting. That is, human glioma cells
confronted with nude mouse brain rather than human
brain may express genes specific to this setting. Two
arguments can be made against this theory. First, there is
no teleological reason for human cells to have an expres-
sion repertoire specific to mouse brain. In fact, there is
an 81% concordance rate between our glioblastoma
xenograft data for genes upregulated at the invasive
tumor edge with p< 0.05 and those data derived from
human samples (publication in preparation). This con-
cordance compares favorably with the 70-85% concord-
ance rate across microarray chip platforms when
hybridizing the same sample RNA [32]. Additionally,
Figure 4 (A) Galectin-1 transfection does not alter U87MG attachment to fibronectin. Attachment to fibronectin-coated 96-well plates was
quantitated with an MTT assay with and without a media change in the middle of the assay. Data were normalized to those of the parental line.
One representative assay is presented. (B) Galectin-1 transfected clones do not proliferate faster than controls. The change in MTS signal
from day 1 is plotted against time. (C) Over-expression of galectin-1 promotes an increased rate of two-dimensional migration. Galectin-1
transfected clones were compared to their GFP control counterparts. (Westerns controlled for loading by β-actin IB). (D) Over-expression of
galectin-1 promotes invasion. All cell counts were normalized to the parental cell line data. (Westerns controlled for loading by β-actin IB).
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invasion has been corroborated previously as detailed
below.
While previous studies from our group [22-24,33,34]
and others [35,36] mainly focused on the effects pro-
voked by lowering galectin-1 expression in GBM cell
biology, the current study focuses of the reverse effects,
e.g. the impact of over expressing galectin-1 in GBM cell
biological behavior. The data from the present study,
which rely on in vitro and in vivo assays of GBM cells
stably transfected to over-express galectin-1, perfectly fit
in with the previous studies mentioned above and high-
light the importance of galectin-1 in the biologically ag-
gressive behavior of experimental GBMs. While there
was no enhancement of proliferation or change inattachment to fibronectin, galectin-1 upregulation
induced more rapid two-dimensional migration and
enhanced transwell invasion. Finally, mice harboring
tumors grown from transfectant clones had shortened
survival compared to those with parental-cell tumors.
More strikingly, the most appropriate control xenografts,
U87-GFP cells, formed tumors in only 7 of 20 implanted
mice. U87 galectin-1 clone tumors showed enhanced
local invasion compared to their parental counterparts.
We did not observe, however, distant invasion in
U87MG tumors over-expressing galectin-1. The U87MG
model is in fact weakly invasive in the brains of immuno-
compromized mice [33,34], while it is associated with
pronounced neoangiogenesis processes [37]. Further
work (e.g. viral transduction) with our patient-derived
Figure 5 Over-expression of galectin-1 in orthotopic xenografts
decreases host survival. Orthotopic xenografts of parental U87G and
galectin-1 transfected cells were established in nude mice. Ten mice
were assigned to each cell line, and each mouse received intracranial
injection of 1 x 106 cells under general anesthesia. At the onset of
neurological symptoms, animals were sacrificed in accordance with the
Mayo Clinic IACUC. Survival curves were generated from those animals
(38 of 40) developing tumors (7 of 20 acGFP-only).
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the in vivo phenotypic alterations that accompany over-
expression of galectin-1.Our model system has identified galectin-1 as a major
regulator of glioma invasion. Lending credence to the
utility of short-passage human-derived xenografts in
modeling tumor biology, the notion of galectin-1 pro-
moting glioma invasion is well-supported by existing
data from our lab and those of others. In fact, these
over-expression data parallel our previous work, showing
that galectin-1 added to the culture media markedly and
specifically increased cell migration levels in human neo-
plastic astrocytes, and that these effects were related to
striking modifications in the organization of the actin
cytoskeleton and an increase in small GTPase RhoA ex-
pression [33]. Conversely, knocking down galectin-1 ex-
pression in U87MG GBM cells by stable transfection
with antisense galectin-1 mRNA, the compliment to our
current study, impairs motility and delays mortality after
their intracranial grafting to nude mice [33]. In addition,
stable transfection with antisense galectin-1 vector
resulted in numerous gene expression alterations and
modification of the actin stress fiber organization [34].
Altogether, the data from previous studies, completed by
the current ones, highlight a major role for galectin-1 in
GBM invasiveness.
The characteristic malignant phenotype of glioblastoma
extends beyond aggressive invasion. This tumor develops
resistance to chemo- and radio-therapy, it promotes
neoangiogenesis, and it seems to benefit from immune
privilege. Interestingly, galectin-1 may play a role in pro-
moting each of these phenotypes. While galectin-1 may be
secreted by GBM in relative hypoxia, it is markedly pro-
angiogenic, and it is taken up by endothelial cells in a
process that activates H-Ras signaling through Raf/Mek/
Erk to promote endothelial proliferation [38-40]. The
standard therapies for GBM – radiation and temozolamide
both promote galectin-1 production, a possible survival re-
action of the tumor [22,36]. Indeed, abrogating galectin-1
expression renders tumor cells more susceptible to temo-
zolamide treatment [22,41]. Finally, galectin-1 induces
apoptosis of activated T-cells [42-46], prevents host ani-
mals from mounting tumor vaccine-induced immunity
[47], and may cooperate with TGF-beta in GBM-induced
immunosuppression [48,49]. In sum, galectin-1 expression
may inversely correlate with patient outcome as evidenced
in previous work [33] and our current study (Additional
file 1). With these important roles outside tumor invasion,
galectin-1 proves to be a model molecule in our xenograft
study. It was identified when searching for invasion media-
tors and understanding its biology leads to a greater
understanding of glioblastoma in general.
In conclusion, the orthotopic glioblastoma xenograft
model recapitulates not only the invasive phenotype, but
also the regional expression profile reported in human
samples of glioblastoma multiforme. The value of the
model (i.e., abundant tissue, high-quality RNA, and
Figure 6 Over-expression of galectin-1 in orthotopic xenografts alters the tumor phenotype. Although the typical U87MG tumor xenograft
is non-invasive, galectin-1 transfected U87MG clones formed tumors showing some invasion at the tumor-brain interface. Selected sections were
stained using a human-specific anti-vimentin antibody.
Toussaint et al. Molecular Cancer 2012, 11:32 Page 10 of 12
http://www.molecular-cancer.com/content/11/1/32fidelity to the human disease) makes it a resource for
identification, as well as preclinical targeting, of novel
mediators of glioma invasion. Galectin-1 was identified
in this manner, and has proven in vitro and in vivo to be
important in the migration and invasion of glioblastoma
cells. Previous work suggests an even greater role of
galectin-1 in GBM neoangiogenesis, chemo- and radio-
resistence, and immune privilege. Targeting this mol-
ecule may offer clinical improvement to the current
standard of glioblastoma therapy, i.e. radiation, temozo-
lomide, anti-angiogenic therapy, and vaccinotherapy.
Additional file
Additional file1: Figure S1. Galectin-1 staining correlates with patient
survival. Using a tissue microarray created at Mayo Clinic, we stained
glioblastoma samples from 34 separate patients using
immunohistochemistry for galectin-1. A survival analysis revealed a trend
towards shorter survival in those patients harboring galectin-1 positive
tumors.
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